Nitin Ohri1, Rafi Kabarriti2, William R Bodner2, Keyur J Mehta2, Viswanathan Shankar3, Balazs Halmos4, Missak Haigentz4, Bruce Rapkin3, Chandan Guha2, Shalom Kalnicki2, Madhur Garg2. 1. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Electronic address: ohri.nitin@gmail.com. 2. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 4. Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Abstract
PURPOSE: To perform a prospective trial testing the feasibility and utility of acquiring activity data as a measure of health status during concurrent chemoradiotherapy. METHODS AND MATERIALS: Ambulatory patients who were planned for treatment with concurrent chemoradiotherapy with curative intent for cancers of the head and neck, lung, or gastrointestinal tract were provided with activity monitors before treatment initiation. Patients were asked to wear the devices continuously throughout the radiation therapy course. Step count data were downloaded weekly during radiation therapy and 2 and 4 weeks after radiation therapy completion. The primary objective was to demonstrate feasibility, defined as collection of step counts for 80% of the days during study subjects' radiation therapy courses. Secondary objectives included establishing step count as a dynamic predictor of unplanned hospitalization risk. RESULTS: Thirty-eight enrolled patients were treated with concurrent chemoradiotherapy. Primary diagnoses included head and neck cancer (n=11), lung cancer (n=13), and a variety of gastrointestinal cancers (n=14). Step data were collected for 1524 of 1613 days (94%) during patients' radiation therapy courses. Fourteen patients were hospitalized during radiation therapy or within 4 weeks of radiation therapy completion. Cox regression modeling demonstrated a significant association between recent step counts (3-day average) and hospitalization risk, with a 38% reduction in the risk of hospitalization for every 1000 steps taken each day (hazard ratio 0.62, 95% confidence interval 0.46-0.83, P=.002). Inferior quality of life scores and impaired performance status were not associated with increased hospitalization risk. CONCLUSION: Continuous activity monitoring during concurrent chemoradiotherapy is feasible and well-tolerated. Step counts may serve as powerful, objective, and dynamic indicators of hospitalization risk.
PURPOSE: To perform a prospective trial testing the feasibility and utility of acquiring activity data as a measure of health status during concurrent chemoradiotherapy. METHODS AND MATERIALS: Ambulatory patients who were planned for treatment with concurrent chemoradiotherapy with curative intent for cancers of the head and neck, lung, or gastrointestinal tract were provided with activity monitors before treatment initiation. Patients were asked to wear the devices continuously throughout the radiation therapy course. Step count data were downloaded weekly during radiation therapy and 2 and 4 weeks after radiation therapy completion. The primary objective was to demonstrate feasibility, defined as collection of step counts for 80% of the days during study subjects' radiation therapy courses. Secondary objectives included establishing step count as a dynamic predictor of unplanned hospitalization risk. RESULTS: Thirty-eight enrolled patients were treated with concurrent chemoradiotherapy. Primary diagnoses included head and neck cancer (n=11), lung cancer (n=13), and a variety of gastrointestinal cancers (n=14). Step data were collected for 1524 of 1613 days (94%) during patients' radiation therapy courses. Fourteen patients were hospitalized during radiation therapy or within 4 weeks of radiation therapy completion. Cox regression modeling demonstrated a significant association between recent step counts (3-day average) and hospitalization risk, with a 38% reduction in the risk of hospitalization for every 1000 steps taken each day (hazard ratio 0.62, 95% confidence interval 0.46-0.83, P=.002). Inferior quality of life scores and impaired performance status were not associated with increased hospitalization risk. CONCLUSION: Continuous activity monitoring during concurrent chemoradiotherapy is feasible and well-tolerated. Step counts may serve as powerful, objective, and dynamic indicators of hospitalization risk.
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Lauren E Cipriano; Dorothy Romanus; Craig C Earle; Bridget A Neville; Elkan F Halpern; G Scott Gazelle; Pamela M McMahon Journal: Value Health Date: 2011-01 Impact factor: 5.725
Authors: Aristotelis Bamias; M Karina; P Papakostas; I Kostopoulos; M Bobos; G Vourli; E Samantas; Ch Christodoulou; G Pentheroudakis; D Pectasides; M A Dimopoulos; G Fountzilas Journal: Cancer Chemother Pharmacol Date: 2010-02-04 Impact factor: 3.333
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Nadia Haj Mohammad; Maarten C C M Hulshof; Jacques J G H M Bergman; Debby Geijsen; Johanna W Wilmink; Mark I van Berge Henegouwen; Hanneke W M van Laarhoven Journal: BMC Cancer Date: 2014-01-31 Impact factor: 4.430
Authors: Brandon Cohen; Samhitha Munugoti; Sonia Kotwani; Lovepreet S Randhawa; Solomon Dalezman; Antonio C Elters; Kate Nam; Jose S Ibarra; Sandheep Venkataraman; William Paredes; Nitin Ohri; Matthew K Abramowitz Journal: Kidney360 Date: 2022-07-13
Authors: Moira A Visovatti; Mi Sook Jung; Heidi Mason; Mary Beth DeRubeis; Francis P Worden; Debra L Barton Journal: Cancer Nurs Date: 2022-01-12 Impact factor: 2.760
Authors: David J Sher; Sepeadeh Radpour; Jennifer L Shah; Nhat-Long Pham; Steve Jiang; Dat Vo; Baran D Sumer; Andrew T Day Journal: JCO Clin Cancer Inform Date: 2022-03
Authors: Gabriel Ruiz Signorelli; Fedor Lehocki; Matilde Mora Fernández; Gillian O'Neill; Dominic O'Connor; Louise Brennan; Francisco Monteiro-Guerra; Alejandro Rivero-Rodriguez; Santiago Hors-Fraile; Juan Munoz-Penas; Mercè Bonjorn Dalmau; Jorge Mota; Ricardo B Oliveira; Bela Mrinakova; Silvia Putekova; Naiara Muro; Francisco Zambrana; Juan M Garcia-Gomez Journal: J Med Internet Res Date: 2019-10-29 Impact factor: 5.428